Effect of Attentional Therapy on Post-traumatic Stress Disorder (NCT05331534) | Clinical Trial Compass
RecruitingNot Applicable
Effect of Attentional Therapy on Post-traumatic Stress Disorder
France140 participantsStarted 2024-02-02
Plain-language summary
Post-traumatic stress disorder (PTSD) is associated with an attentional bias towards negative stimuli, which is supposed to contribute to the development and the maintenance of the disorder. We recently showed using eye-tracking evidenced two types of AB towards negative stimuli: a "physiological AB" found both in healthy and individual with PTSD, characterized by a stronger initial attentional engagement towards negative stimuli compared to neutral stimuli, as revealed by longer first fixation duration dwell time on negative pictures than on neutral pictures; a "pathological bias" observed only in individuals with PTSD and characterized by an heightened sustained attention towards negative stimuli once detected, which further increases with prolonged exposure. The present study aimed at assessing the effectiveness of an eye-tracking assisted attentional bias reduction therapy, targeting specifically the pathological bias on the reduction of PTSD symptoms
Who can participate
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Understanding and able to express themselves in French
* Giving informed consent, by dating and signing the study participation form
* Having health insurance coverage
* Normal or corrected to normal vision and hearing
* DSM-5 PTSD criteria, assessed using the CAPS and PCL-5
Exclusion Criteria:
* Minors or adults under guardianship, under judicial protection, persons deprived of liberty
* Pregnant or breastfeeding women
* Refusal to participate after being clearly and fairly informed about the study
* Sensory, visual or auditory incapacity to participate in the study
* Personal history of neurological disorder or current neurological disorder
* Use of drugs other than tobacco and alcohol
* Alcohol use on the day of experimentation
* Personal history of psychiatric disorders or current psychiatric disorders other than anxiety, depressive, or trauma and stress disorders assessed at clinical interview and with MINI
* Personal history of multiple trauma in childhood
* Psychotropic medication treatment not stabilized over the past 4 weeks
* MOCA \< 26
* Contraindication to prolonged exposure therapy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
PTSD symptomatology assessed using the Clinician-Administered PTSD Scale (CAPS) score.
Timeframe: Before and after ACTo or ACT treatment: at day 1 and 1 month after inclusion